TABLE 5.

Kind and incidence of fungal postprophylaxis end points according to the classification of the Expert Committee for eligible patients

Eligible patient analysis parametera	No. % of patients with end point posttreatment		Pb
	Itraconazole (n = 201)	Amphotericin B (n = 186)
Invasive aspergillosis	5 (2.5)c	9 (4.8)d	0.216
Proven deep fungal infection (including invasive aspergillosis)	8 (4.0)c	12 (6.5)e	0.273
Superficial fungal infection	2 (1.0)	11 (5.9)	0.007
Total proven fungal infection	10 (5.0)	23 (12.4)	0.009
Suspected deep fungal infection (including fever of unknown origin)	75 (37.3)	73 (39.2)	0.696

^aPatients were classified as eligible with a neutrophil count of <0.5 × 10⁹/liter for at least 14 days. 

^bIntergroup comparison, chi-square test. 

^cOne died. 

^dFour died. 

^eFive died.